BR100 Decreased By (-0.15%)
BR30 Decreased By (-0.44%)
KSE100 Decreased By (-0.09%)
KSE30 Decreased By (-0.01%)
AGHA 6.61 Decreased By ▼ -0.06 (-0.9%)
BECO 4.37 Increased By ▲ 0.02 (0.46%)
BML 55.11 Decreased By ▼ -1.06 (-1.89%)
BOP 29.98 Decreased By ▼ -0.14 (-0.46%)
CNERGY 12.78 Decreased By ▼ -0.20 (-1.54%)
CSIL 5.20 Decreased By ▼ -0.11 (-2.07%)
FCCL 51.68 Increased By ▲ 0.03 (0.06%)
FFL 14.43 Decreased By ▼ -0.06 (-0.41%)
FNEL 1.20 Decreased By ▼ -0.01 (-0.83%)
KEL 6.03 Decreased By ▼ -0.03 (-0.5%)
KOSM 5.44 Decreased By ▼ -0.40 (-6.85%)
LOTCHEM 26.25 Increased By ▲ 0.08 (0.31%)
MLCF 91.40 Increased By ▲ 0.17 (0.19%)
NBP 162.30 Decreased By ▼ -1.89 (-1.15%)
NCPL 52.67 Decreased By ▼ -0.51 (-0.96%)
NPL 58.00 Decreased By ▼ -1.12 (-1.89%)
OGDC 315.00 Increased By ▲ 1.61 (0.51%)
PACE 9.75 Decreased By ▼ -0.02 (-0.2%)
PAEL 35.00 Decreased By ▼ -0.24 (-0.68%)
PIBTL 14.29 Decreased By ▼ -0.42 (-2.86%)
PPL 220.59 Decreased By ▼ -0.77 (-0.35%)
PRL 90.30 Decreased By ▼ -0.92 (-1.01%)
PTC 59.30 Increased By ▲ 0.11 (0.19%)
SSGC 23.40 Increased By ▲ 0.10 (0.43%)
TBL 8.69 Decreased By ▼ -0.06 (-0.69%)
TELE 7.44 Decreased By ▼ -0.17 (-2.23%)
TPL 21.10 Decreased By ▼ -0.93 (-4.22%)
TPLP 12.15 Decreased By ▼ -0.41 (-3.26%)
TREET 21.52 Decreased By ▼ -0.21 (-0.97%)
TRG 54.64 Decreased By ▼ -1.15 (-2.06%)
World

UK health minister says data on Pfizer vaccine supports shift to 12-week dosing schedule

  • Around 89% efficacy comes from between days 14 and days 21 after the first dose," Hancock told lawmakers.
Published Updated
By

LONDON: Data supports Britain's decision to move to a 12-week dosing schedule for Pfizer's COVID vaccine, health minister Matt Hancock said on Thursday, adding details on efficacy gathered during the rollout would be published as soon as possible.

"Around 89% efficacy comes from between days 14 and days 21 after the first dose," Hancock told lawmakers, saying he had reviewed the data, and that it supported the decision to move to a 12-week schedule between doses.

"We're looking at this data, and in fact we're measuring the efficacy here at home for those who've been vaccinated, by matching the data between those who've been vaccinated and those who test positive. And we're monitoring that and we will publish that data as soon as it is clinically valid."

Comments

Comments are closed for this article.